Mirum Pharmaceuticals, Inc. MIRM
Institutional shares held
53.8 Million
2.6K
calls
99.7K
puts
Total value of holdings
$2.81B
$135K
calls
$5.2M
puts
Market Cap
$1.95B
36,751,700
Shares Out.
Institutional ownership
146.42%
# of Institutions
211
We take great care to ensure that the data presented and summarized in this overview for Mirum Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MIRM
View all-
Frazier Life Sciences Management, L.P. Menlo Park, CA6.57MShares$349 Million16.29% of portfolio
-
Janus Henderson Group PLC London, X04.58MShares$244 Million0.1% of portfolio
-
Black Rock Inc. New York, NY3.24MShares$172 Million0.0% of portfolio
-
Bvf Inc San Francisco, CA2.8MShares$149 Million4.33% of portfolio
-
Eventide Asset Management, LLC Boston, MA2.61MShares$139 Million2.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.42MShares$129 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.51MShares$80.3 Million0.01% of portfolio
-
Novo Holdings Hellerup, G71.5MShares$79.7 Million5.04% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD1.47MShares$78.2 Million2.43% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.42MShares$75.6 Million0.01% of portfolio
Latest Institutional Activity in MIRM
Top Purchases
Top Sells
About MIRM
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
Insider Transactions at MIRM
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 03
2025
|
Jolanda Howe SVP, GLOBAL CONTROLLER |
SELL
Open market or private sale
|
Direct |
1,064
-20.09%
|
$51,072
$48.22 P/Share
|
|
Feb 03
2025
|
Christopher Peetz CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
9,102
-7.28%
|
$436,896
$48.22 P/Share
|
|
Feb 03
2025
|
Peter Radovich PRESIDENT AND COO |
SELL
Open market or private sale
|
Direct |
2,627
-8.88%
|
$126,096
$48.22 P/Share
|
|
Jan 31
2025
|
Jolanda Howe SVP, GLOBAL CONTROLLER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,772
+25.07%
|
-
|
|
Jan 24
2025
|
Peter Radovich PRESIDENT AND COO |
SELL
Open market or private sale
|
Direct |
3,177
-9.7%
|
$149,319
$47.92 P/Share
|
|
Jan 24
2025
|
Christopher Peetz CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
6,837
-5.19%
|
$321,339
$47.92 P/Share
|
|
Jan 24
2025
|
Jolanda Howe SVP, GLOBAL CONTROLLER |
SELL
Open market or private sale
|
Direct |
902
-20.38%
|
$42,394
$47.92 P/Share
|
|
Jan 23
2025
|
Eric Bjerkholt CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,667
+6.91%
|
-
|
|
Jan 23
2025
|
Peter Radovich PRESIDENT AND COO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,750
+14.93%
|
-
|
|
Jan 23
2025
|
Christopher Peetz CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+8.66%
|
-
|
|
Jan 23
2025
|
Jolanda Howe SVP, GLOBAL CONTROLLER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+25.31%
|
-
|
|
Jan 17
2025
|
Joanne Quan CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
6,969
-55.23%
|
$313,605
$45.86 P/Share
|
|
Jan 16
2025
|
Joanne Quan CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+49.77%
|
-
|
|
Jan 07
2025
|
Christopher Peetz CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
7,489
-5.9%
|
$314,538
$42.82 P/Share
|
|
Jan 07
2025
|
Peter Radovich PRESIDENT AND COO |
SELL
Open market or private sale
|
Direct |
1,998
-6.89%
|
$83,916
$42.82 P/Share
|
|
Jan 07
2025
|
Jolanda Howe SVP, GLOBAL CONTROLLER |
SELL
Open market or private sale
|
Direct |
750
-20.4%
|
$31,500
$42.82 P/Share
|
|
Jan 06
2025
|
Jolanda Howe SVP, GLOBAL CONTROLLER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+25.38%
|
-
|
|
Nov 14
2024
|
Jolanda Howe SVP, GLOBAL CONTROLLER |
SELL
Open market or private sale
|
Direct |
2,500
-50.75%
|
$117,500
$47.1 P/Share
|
|
Nov 14
2024
|
Jolanda Howe SVP, GLOBAL CONTROLLER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+33.67%
|
$5,000
$2.94 P/Share
|
|
Nov 08
2024
|
Joanne Quan CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
118
+50.0%
|
$2,478
$21.05 P/Share
|
Last 12 Months Summary
Buy / Acquisition
136K
Shares
From
13
Insiders
| Open market or private purchase | 4.35K shares |
|---|---|
| Exercise of conversion of derivative security | 129K shares |
| Grant, award, or other acquisition | 2.04K shares |
Sell / Disposition
186K
Shares
From
7
Insiders
| Bona fide gift | 103K shares |
|---|---|
| Open market or private sale | 83.7K shares |